Solid tumors and advanced therapies: why science alone will not deliver the cure
Year: 2026
Type: article
Abstract: Despite remarkable progress in hematologic cancers, advanced therapies (CAR-T, TCR, in vivo CARs, and engineered immune cells) have consistently failed to deliver durable benefit in solid tumors (with the exception of lifileucel and afamitresgene autoleucel). The underlying causes are not purely biological. The tumor microenvironment (TME) is indeed a formidable, multifactorial barrier: a physical and chemical fortress that limits infiltration, perfusion, and persistence. Yet scientific innovation alone cannot solve what is equally a translational and systemic challenge. Capital irrationality, fragmented IP strategies, and the lack of a rational, product-oriented mindset are stalling genuine progress.
Source: Cell and Gene Therapy Insights
Author: Arnaud Deladeriere
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7131659533
FWCI:
Cites:
Cited by:
Related to: